Want to see IN:JHS full AI Analyst Report?
Top Page
JHS Svendgaard Laboratories Limited
(JHS)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹8.50
▲(14.71% Upside)
Action:Reiterated
Date:08/18/26
The score is primarily held back by weak financial performance—continued losses, margin pressure, and recurring negative operating/free cash flow—despite a solid low-leverage balance sheet. Technicals provide a partial offset with improving short- to mid-term momentum (above key moving averages and positive MACD), while valuation remains pressured due to negative earnings and no dividend support.
Positive Factors
Revenue Recovery
The FY2026 rebound indicates renewed demand for JHS’s manufactured consumer products. Sustained volume recovery could improve facility utilization and operating leverage, although consistency across future periods remains important.
Negative Factors
Persistent Net Losses
Continuing losses show that revenue recovery has not yet translated into sustainable shareholder returns. Negative operating earnings limit internal funding capacity and leave the business exposed if pricing, costs, or production volumes deteriorate.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The FY2026 rebound indicates renewed demand for JHS’s manufactured consumer products. Sustained volume recovery could improve facility utilization and operating leverage, although consistency across future periods remains important.
Read all positive factors
JHS Svendgaard Laboratories Limited (JHS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹717.60M
Dividend YieldN/A
Average Volume (3M)16.78K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth19.41%
EPS Growth89.58%
CountryIN
Employees250
SectorGeneral
Sector StrengthN/A
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.23
Shares Outstanding87,405,770
10 Day Avg. Volume16,348
30 Day Avg. Volume16,781
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)0.33
Price to Sales (P/S)0.56
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
JHS Svendgaard Laboratories Limited Business Overview & Revenue Model
Company Description
JHS Svendgaard Laboratories Limited, along with its associated companies, specializes in the manufacturing and sale of a diverse array of oral and dental hygiene products, catering to both adults and children throughout India. Their extensive prod...
How the Company Makes Money
JHS primarily makes money by manufacturing and supplying finished consumer products (notably oral care products such as toothpaste) to customers and receiving revenue from the sale of those goods. A key revenue stream is typically contract manufac...
JHS Svendgaard Laboratories Limited Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.02B | 919.97M | 698.06M | 840.82M | 854.91M |
| Gross Profit | 177.22M | 309.55M | 203.55M | 165.45M | 201.68M |
| EBITDA | 60.64M | -39.92M | 33.78M | -163.82M | 85.45M |
| Net Income | -19.22M | -197.44M | -40.58M | -175.17M | -40.52M |
Balance Sheet | |||||
| Total Assets | 2.15B | 2.01B | 1.97B | 2.28B | 2.22B |
| Cash, Cash Equivalents and Short-Term Investments | 191.00M | 200.16M | 94.56M | 386.51M | 80.19M |
| Total Debt | 148.51M | 64.58M | 51.29M | 155.09M | 61.82M |
| Total Liabilities | 405.49M | 284.41M | 271.70M | 543.87M | 269.46M |
| Stockholders Equity | 1.75B | 1.73B | 1.70B | 1.74B | 1.86B |
Cash Flow | |||||
| Free Cash Flow | -148.91M | -157.11M | -401.17M | 89.43M | -158.75M |
| Operating Cash Flow | -20.97M | -51.78M | -85.84M | 232.86M | -91.36M |
| Investing Cash Flow | -130.38M | -220.18M | -217.34M | 96.77M | -46.97M |
| Financing Cash Flow | 121.43M | 232.97M | 21.74M | -9.00M | -16.72M |
JHS Svendgaard Laboratories Limited Technical Analysis
Negative
7.41
Price Trends
7.82
Positive
8.23
Negative
9.25
Negative
Market Momentum
0.20
Negative
52.23
Neutral
31.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Negative. The current price of 7.41 is below the 20-day moving average (MA) of 8.07, below the 50-day MA of 7.82, and below the 200-day MA of 9.25, indicating a neutral trend. The MACD of 0.20 indicates Negative momentum. The RSI at 52.23 is Neutral, neither overbought nor oversold. The STOCH value of 31.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JHS.
JHS Svendgaard Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹514.04B | 38.12 | ― | 2.30% | 3.79% | -3.28% | |
69 Neutral | ₹177.02B | 23.48 | ― | 3.38% | 2.82% | -8.52% | |
69 Neutral | ₹157.45B | 62.99 | ― | ― | 21.08% | 237.19% | |
65 Neutral | ₹707.10B | 36.02 | ― | 1.95% | 7.40% | 10.63% | |
59 Neutral | ₹953.67B | 49.87 | ― | 1.89% | 9.22% | 3.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹717.60M | -37.68 | ― | ― | 19.41% | 89.58% |
* General Sector Average
IN:JHS
JHS Svendgaard Laboratories Limited
8.21
-2.70
-24.75%
IN:COLPAL
Colgate-Palmolive (India) Limited
1,889.95
-343.21
-15.37%
IN:DABUR
Dabur India Limited
398.60
-110.42
-21.69%
IN:EMAMILTD
Emami Limited
403.15
-170.55
-29.73%
IN:GODREJCP
Godrej Consumer Products Limited
931.95
-307.95
-24.84%
IN:HONASA
Honasa Consumer Limited
482.95
183.90
61.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.